Format

Send to

Choose Destination
Expert Rev Clin Immunol. 2014 Jun;10(6):771-80. doi: 10.1586/1744666X.2014.904747. Epub 2014 Apr 1.

Breaking the mould - novel diagnostic and therapeutic strategies for invasive pulmonary aspergillosis in the immune deficient patient.

Author information

1
Biosciences, University of Exeter, Geoffrey Pope Building, Exeter, EX4 4QD, UK.

Abstract

Invasive pulmonary aspergillosis (IPA) caused by the ubiquitous environmental fungus Aspergillus is a frequently fatal lung disease of immunocompromised humans accounting for more than 200,000 infections each year, with an associated mortality rate of 30-90%. This review addresses the current status of IPA diagnosis and treatment and the urgent need to develop accurate, non-invasive strategies for identifying pulmonary infections in the ever-expanding population of immune deficient patients at risk of acquiring opportunistic fungal infections including hematological malignancy and hematopoetic stem cell transplant patients. Recent advances in the use of an Aspergillus-specific monoclonal antibody, JF5, for point-of-care diagnosis of IPA using lateral-flow technology is examined, as is its use in PET/MRI bioimaging and radio-immunotherapy using radionuclide-labeled single chain antibody fragments, Fab fragments, and a fully humanized JF5 derivative.

KEYWORDS:

PET/MRI; bioimaging; hematological malignancy; invasive pulmonary aspergillosis; monoclonal antibody; radioimmunotherapy; stem cell transplant; vaccine

PMID:
24689528
DOI:
10.1586/1744666X.2014.904747
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center